Intelligent Bio Solutions reported strong fiscal Q1 2027 results, with record revenue driven by cartridge sales and a narrowed net loss. The company's operational growth and progress towards entering the U.S. drug screening market indicate positive momentum, potentially boosting investor confidence.
Intelligent Bio Solutions (INBS) announced record fiscal first-quarter 2027 revenue of $1.39 million, a 25.2% year-over-year increase, primarily driven by a 32% rise in cartridge sales. The company also significantly narrowed its net loss to $2.65 million from $2.98 million in the prior year, and its loss per share improved from $3.49 to $0.86. This strong financial performance, coupled with operational milestones like increased active customer accounts and reader installations, and strategic progress with ISO recertification and 510(k) submission for the U.S. drug screening market, suggests positive momentum. For traders, this indicates a potential short-term positive catalyst for INBS stock due to improved financials and long-term growth opportunities in a new market, though continued profitability remains a key risk.